Health Condition 1: Z471- Aftercare following joint replacement surgery Health Condition 2: null- Patients undergoing elective knee or hip surgery
Conditions
Interventions
None listed
Sponsors
Virchow Biotech Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Male or Female patients who are undergoing elective hip or knee replacement surgery
Exclusion criteria
Exclusion criteria: Patients with active bleeding or a high risk of bleeding that contraindicated the use of rivaroxaban ; Other exclusion criteria included conditions preventing bilateral venography, clinically significant liver, cardiac, renal disease, concomitant use of protease inhibitors of the human immunodeficiency virus or fibrinolytic agents, planned intermittent pneumatic compression, requirement of ongoing anticoagulant therapy, and pregnancy or breast-feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Any Major BleedingTimepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Any Minor BleedingTimepoint: 3 months | — |
Countries
India
Contacts
Public ContactDr Hemanth Nandigala
Virchow Biotech Private Limited
Outcome results
None listed